
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Equities researchers at Brookline Capital Markets upped their Q4 2026 earnings per share estimates for shares of Candel Therapeutics in a research note issued to investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.32). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.29) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.42) EPS.
CADL has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Bank of America upgraded Candel Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $12.00 to $18.00 in a report on Monday, September 21st. UBS Group reaffirmed a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. Jefferies Financial Group assumed coverage on Candel Therapeutics in a report on Thursday, October 22nd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group dropped their target price on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.29.
Read Our Latest Analysis on Candel Therapeutics
Candel Therapeutics Stock Down 6.3%
Shares of CADL stock opened at $5.81 on Tuesday. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00. The firm’s fifty day moving average price is $9.61 and its two-hundred day moving average price is $8.39. The firm has a market capitalization of $444.58 million, a P/E ratio of -3.93 and a beta of -0.27.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at about $51,181,000. Goldman Sachs Group Inc. grew its holdings in Candel Therapeutics by 4.1% during the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock worth $3,316,000 after purchasing an additional 12,385 shares during the period. Bank of America Corp DE bought a new position in Candel Therapeutics during the second quarter worth about $2,873,000. Wellington Management Group LLP bought a new position in Candel Therapeutics during the second quarter worth about $2,119,000. Finally, Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the second quarter worth approximately $1,975,000. Institutional investors own 13.93% of the company’s stock.
Trending Headlines about Candel Therapeutics
Here are a few of the latest headlines about CADL:
- Positive Sentiment: Citigroup lowered its price target from $26 to $20 but maintained a Buy rating, implying substantial upside from the cited share price. Citigroup rating
- Negative Sentiment: Candel pushed the aglatimagene BLA submission to mid-2027. The delay followed earlier statements about filing timing and came after the company raised $80 million partly to prepare the application, prompting a sharp selloff and continued pressure on the shares. The Pharma Letter article
- Negative Sentiment: HC Wainwright, Canaccord Genuity, and Stifel Nicolaus also reportedly reduced their price targets, reflecting a more cautious outlook following the filing delay. HC Wainwright price target report
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
